Ocular Therapeutix Stock News

Ocular Therapeutix press release (NASDAQ:OCUL): Q4 GAAP EPS of -$0.23 in-line.Revenue of $12.31M (+67.5% Y/Y) misses by $2.13M.

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline. “Ocular has had another strong quarter and a productive year,” said Antony Mattessich, President and Chief Executive Officer. “Our comme

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.

Ocular Therapeutix <> 10% owner, Summer Road LLC, bought 50,000 shares of the company in a price range of $5.78-6.45, worth ~$300K.This brings his total share holding to

Ocular Therapeutix <> said AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China to evaluate the safety and efficacy of DEXTENZA (0.4

Ocular Therapeutix: Shaken By Covid, Perfectly Positioned For Long-Term Gains

Ensysce Biosciences (NASDAQ:ENSC) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation. Institutional & Insider Ownership 98.5% of Ensysce Biosciences shares are held by institutional investors. Comparatively, […] The post Ensysce Biosciences (NASDAQ:ENSC) vs. Ocular Therapeutix (NASDAQ:OCUL) Critical Survey appeared first on ETF Daily News .

Ocular Therapeutix, Inc. (NASDAQ:OCUL) major shareholder Summer Road Llc bought 10,510 shares of the stock in a transaction on Monday, December 13th. The shares were bought at an average cost of $6.50 per share, with a total value of $68,315.00. The acquisition was disclosed in a document filed with the SEC, which is available at []

Ocular Therapeutix, Inc. (NASDAQ:OCUL) major shareholder Summer Road Llc acquired 10,510 shares of the stock in a transaction dated Monday, December 13th. The shares were purchased at an average cost of $6.50 per share, with a total value of $68,315.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which []